## FORM 4

obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL

OMB Number: Estimated average burden hours per response: 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					OI .	Secu	011 30(11) (	oi tile	invesimen	t Con	ipariy Aci	01 1940							
					Issuer Name <b>and</b> Ticker or Trading Symbol IOPHARM ONCOLOGY INC [ ZIOP ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
IXIIXIX	MINDIII	<u> </u>			1									)	Direct	or		10% O	wner
(Last)	(Fi	rst)	(Middle)					t Tran	saction (Mo	onth/[	Day/Year)			1	Officer below)	(give title		Other ( below)	specify
C/O THI	RD SECUE	RITY, LLC			07/	31/2	2018												
	OVE AVE																		
1001 GIV	OVETIVE	NOL			4. If	f Ame	endment,	Date	of Original	Filed	(Month/D	ay/Year)		6. In	dividual or	Joint/Group	o Filin	g (Check Ap	plicable
(Street)														Line	•				.
RADFO	RD V	A :	24141											,	Form	•		orting Person n One Repo	
-														1	Perso	n			
(City)	(S	tate)	(Zip)																
		Tab	le I - Nor	-Deriv	ative	Se	curitie	s Ac	quired,	Dis	posed o	of, or Be	enef	iciall	y Owne	t			
1. Title of S	Security (Inst	tr. 3)		2. Trans	action		2A. Deem		3.			ities Acqui			5. Amou				7. Nature
Date				Date   (Month/I	Dav/Ye		Execution Date, if any		Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4			, 4 and	Securiti Benefic			orm: Direct	of Indirect Beneficial
				(	,.		(Month/Da	ay/Yea			'				Owned	Following   (l) (lı		nstr. 4)	Ownership
									Code	v	Amount	(A)	or Price		Transac	Reported Transaction(s)			(Instr. 4)
									Code	<u> </u>	Amount	(D)		-1106	(Instr. 3	and 4)			
		Т	able II - I									•		-	Owned				
				e.g., p	uts,	call	s, warr	ants	s, option	s, c	onverti	ble sec	uriti	ies)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	n Date Execution Date, if any (Month/Day/Year)			4. Transaction Code (Instr. 8)		n of		6. Date Exercisa Expiration Date (Month/Day/Year		Amount of		of s ng e Security nd 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	or Nui of	ount mber ares					
Series 1 Preferred Stock	(1)	07/31/2018			J		1,270		(1)		(1)	Common Stock		(1)	(2)	128,272	(2)	I	by Intrexon <sup>(3)</sup>
1. Name ar	nd Address of	Reporting Person*																	

f Reporting Person*							
<u>L J</u>							
(First)	(Middle)						
C/O THIRD SECURITY, LLC							
NUE							
VA	24141						
(State)	(Zip)						
*							
f Reporting Person*							
Reporting Person  ORP							
	(Middle)						
<u>ORP</u>	(Middle)						
(First)	,						
ORP  (First)  RTMENT	,						
ORP (First) .RTMENT EADOWS PARKWA	AY						
ORP  (First)  RTMENT	,						
	L J  (First)  RITY, LLC  NUE  VA  (State)						

## **Explanation of Responses:**

1. Each share of Series 1 Preferred Stock ("Preferred Stock") has a stated value of \$1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock. The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation ("Intrexon") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the "Issuance Agreement"). The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016.

2. Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly

dividend payable in additional shares of Preferred Stock equal to \$12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of \$1,200, rounded down to the nearest whole share.

3. Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

<u>/s/ Randal J. Kirk</u> <u>07/31/2018</u>

/s/ Randal J. Kirk, CEO of Intrexon Corporation

07/31/2018

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.